Skip to main content
Internal view of patient's torso demonstrating targeted accuracy of TheraSphere Y-90 Glass Microspheres in liver.

TheraSphere™ Y-90 Glass Microspheres

ROWAN study

ROWAN study overview

ROWAN will explore if there is a synergistic benefit of TheraSphere Y-90 Glass Microspheres with immunotherapy to improve response to cancer therapy in early and intermediate stage HCC patients.

TheraSphere clinical program enrolling more than 1,800 patients worldwide.

Chart of TheraSphere Clinical Series: HCC, with Dosisphere-01, prospective, randomized (56), Legacy, retrospective (162), Target, retrospective, global (211), Proactif, prospective spot-approval study (France only) (500), Stop HCC, prospective, randomized, global (526); Future Clinical Applications: mCRC, HCC +/- Immuno, Epoch, prospective, randomized, global (428), Rowan, prospective, randomized, global (150). TheraSphere clinical series HCC

*CAUTION:  In the U.S. TheraSphere is under an investigational device exemption for treatment of patients with metastatic colorectal cancer. The safety and effectiveness for this treatment has not been established.

Rowan Study.

TheraSphere is a registered trademark of Theragenics Corporation used under license by Biocompatibles UK Ltd., a wholly owned subsidiary of Boston Scientific Corporation.